Clinical Trial Update: Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of combining lenvatinib with pembrolizumab in patients with advanced melanoma previously treated with anti-PD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2024-10-09